Matthew Giust
Impact in
- Ophthalmology top 0.2%
- Retinal Diseases and Treatments
- Retinal and Optic Conditions
- Ocular Diseases and Behçet’s Syndrome
- Glaucoma and retinal disorders
-
- Retinal Imaging and Analysis
- Retinal and Macular Surgery
- Corneal Surgery and Treatments
Papers in
-
- Retinal Diseases and Treatments 3
- Retinal and Optic Conditions 2
- Ocular Diseases and Behçet’s Syndrome 1
-
- Retinal Imaging and Analysis 2
- Retinal and Macular Surgery 1
- Co-authors
- Dante J. Pieramici (3 shared papers)Alessandro Castellarin (3 shared papers)Robert L. Avery (3 shared papers)Ma'an Nasir (3 shared papers)Melvin Rabena (3 shared papers)Arun Patel (1 shared paper)Joel Pearlman (1 shared paper)Robert Wendel (1 shared paper)
- Partner nations
- United States
In The Last Decade
Matthew Giust
3 papers receiving 1.5k citations
Matthew Giust's Hit Papers
Peers
Comparison fields: 5 of 59
- Ophthalmology 1.4k
- Radiology, Nuclear Medicine and Imaging 1.1k
- Neurology 70
- Molecular Biology 279
- Clinical Biochemistry 21
Countries citing papers authored by Matthew Giust
This map shows the geographic impact of Matthew Giust's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Giust with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Giust more than expected).
Fields of papers citing papers by Matthew Giust
This network shows the impact of papers produced by Matthew Giust. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Giust. The network helps show where Matthew Giust may publish in the future.
Co-authors
The 8 scholars most cited alongside Matthew Giust, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration Hit paper breakdown → | 2006 | 953 |
| 2 | Intravitreal Bevacizumab (Avastin) in the Treatment of Proliferative Diabetic Retinopathy Hit paper breakdown → | 2006 | 603 |
| 3 | Intravitreal Bevacizumab (Avastin®) in the Surgical Treatment of Proliferative Diabetic Retinopathy | 2007 | 1 |
About Matthew Giust
Matthew Giust is a scholar working on Ophthalmology, Radiology, Nuclear Medicine and Imaging, Infectious Diseases, Organic Chemistry and Surgery, having authored 3 papers that have together received 1.6k indexed citations. Recurring topics across this work include Retinal Diseases and Treatments (3 papers), Retinal Imaging and Analysis (2 papers), Retinal and Optic Conditions (2 papers), Ocular Diseases and Behçet’s Syndrome (1 paper) and Retinal and Macular Surgery (1 paper). The work is most often cited by research in Ophthalmology (1.4k citations), Radiology, Nuclear Medicine and Imaging (1.1k citations), Neurology (70 citations), Molecular Biology (279 citations) and Clinical Biochemistry (21 citations). Matthew Giust has collaborated with scholars based in United States. Frequent co-authors include Dante J. Pieramici, Alessandro Castellarin, Robert L. Avery, Ma'an Nasir, Melvin Rabena, Arun Patel, Joel Pearlman and Robert Wendel. Their work appears in journals such as Ophthalmology and Investigative Ophthalmology & Visual Science.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.